Navigating Change in the U.S. Healthcare System - Susan Dentzer, President & CEO of America’s Physician Groups

12/19/22 • 39 min

We welcome one of the nation's most respected health and health policy thought leaders to Raise the Line on this episode. Susan Dentzer’s remarkable career includes many years of reporting on healthcare for major national news outlets, being a senior policy adviser to the Robert Wood Johnson Foundation and serving as a board leader in medical education and health system delivery, just to name a few of her contributions. Earlier this year, Ms. Dentzer was appointed president and CEO of America's Physician Groups, an organization representing more than 350 physician groups providing coordinated, value-based healthcare for more than ninety million patients nationwide. She's also currently board chair of Research America, which advocates on behalf of biomedical and health-related research and innovation. Tune in to this elucidating discussion with host Shiv Gaglani that delves into what the pandemic revealed about value-based care and virtual care; what is helping to lessen clinician burnout; surprising views among medical students on the use of tech in healthcare; what is at the root of the public’s mistrust of science, and much more. “The reality of healthcare is very complicated. What I would make a plea for is that we all try to engage in developing a greater understanding of the issues, as opposed to seeing them through a narrow lens.”

Mentioned in this episode:
https://www.apg.org/
https://www.researchamerica.org/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Mentioned in this episode:
https://www.apg.org/
https://www.researchamerica.org/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Previous Episode

A Reservoir of Hope Drives Research Into a Rare Brain Disorder - Scott Reich, Co-Founder of Believe in a Cure

“There's a reservoir of hope, energy and optimism many of us have that we may not know about until we're really tested,” says attorney and author Scott Reich. The heavy test he and his wife Ilissa have endured for the past three years started when their infant son Eli was diagnosed with a rare brain disorder called FOXG1 Syndrome which causes severe seizures and impedes normal movement, speech and sleep, among other problems. Scott vividly recalls the moment when Eli’s doctor explained there was no hope for treatments or a cure. “I just felt an instantaneous gravitational pull that despite the intense emotion that overtook us in the doctor's office, we were going to do something about it.” That “something” includes starting the nonprofit foundation Believe in a Cure which is currently funding over fifty research and development projects worldwide focused on this pernicious disorder. Join us for this enlightening conversation with host Shiv Gaglani to learn about the multi-pronged strategy scientists are pursuing to overcome the mutation in this so-called master gene, the promising results emerging from preclinical programs and the supportive global community Believe in a Cure has helped create for the hundreds of other families fighting the same battle.

Mentioned in this episode: https://www.webelieveinacure.org

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Next Episode

undefined - Using AI to Solve Medical Mysteries and Spur Rare Disease Treatments – Dr. Matthew Might, Kaul Precision Medicine Institute at the University of Alabama at Birmingham

Using AI to Solve Medical Mysteries and Spur Rare Disease Treatments – Dr. Matthew Might, Kaul Precision Medicine Institute at the University of Alabama at Birmingham

“It's still early days in the application of all this technology relative to its long-term potential, but even so, it's already producing some big wins for patients,” says Dr. Matthew Might, whose impactful career in computer science and medicine has been shaped by the rare disease odyssey of one of his children. His son, Bertrand, was the first person in the world diagnosed with a particular form of NGLY1 deficiency, a neurogenic degenerative condition that causes developmental delays, seizures and frequent infections. Unfortunately, Bertrand succumbed to an infection at the age of twelve in 2020 but by that time, Dr. Might's work in precision medicine had led to crucial discoveries for dozens of children with NGLY1 deficiency. Now, as director of the Hugh Kaul Institute of Precision Medicine at the University of Alabama at Birmingham, he uses an AI-based system programmed to connect the dots in extensive databases of medical literature to make inferences about potential therapies for uncommon diseases. Check out this fascinating conversation with host Shiv Gaglani about the promise of this approach, the challenges in repurposing drugs and conducting clinical trials in the rare disease community, the need for more genetic counselors and Dr. Might’s work on President Obama’s Precision Medicine Initiative, which he calls the Rosetta stone of the human genome.

Mentioned in this episode: https://www.uab.edu/medicine/pmi/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast